Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

European Funding Boosts Research into Breast Cancer

29.04.2005


As cancer is the main cause of death among women aged 35 to 64 the EU’s Sixth Framework Programme (FP6) has agreed to provide seven million euros for a new Network of Excellence called TRANS-BIG, aimed at addressing the treatment of breast cancer.



TRANS-BIG aims to refine the diagnosis of breast cancer in a way that will enable specialists reduce the number of women being over treated by better identification of those who will benefit from treatment.

“Under the present system many patients are over treated while only a few derive a considerable benefit”, says Dr Robert Leonard from the South West Wales Cancer Institute. “By refining the prognosis for a better definition of who needs treatment we hope to significantly reduce the proportion of women receiving unnecessary chemotherapy and reduce their exposure to toxicity and harmful long-term side effects. At the same time, this will considerably reduce the cost of breast cancer therapy and its burden on European health care systems.


“Indeed, two decades of clinical trials have shown that although chemotherapy increases the survival rate from 2 to 12 per cent, it can also be the cause of secondary cancers, cardiac toxicity, early menopause and a reduction in cognitive functions.”

The TRANS-BIG Network of Excellence, based on the principles of translational research - ’bench to bedside’ and ’bedside to bench’ - will tackle the fragmentation which currently exists in this field of research and accelerate the clinical applications of biological discoveries.

With 39 partners from 21 countries the TRANS-BIG consortium has the critical mass expertise needed to create a fully coherent research force of leading specialists in Europe. This in itself will help overcome the existing fragmentation of effort and give Europe the competitive approach it needs to take the lead in breast cancer therapy internationally.

The first target of TRANS-BIG is the development of its first trial - MINDACT (Microarray for Node Negative Disease may avoid Chemotherapy) - using microarrays to identify the specific molecular make up (’signature’) of a tumour. Although still in its infancy, this technology is expected to allow for a better selection of the patients that actually do need chemotherapy.

“We believe that the results of MINDACT will show that using the new technology to assess risk will result in fewer women being treated unnecessarily”, added Dr Leonard. “This, in turn, will mean that fewer women will suffer from the unpleasant side effects of chemotherapy. Not only will the overall quality of life of breast cancer patients be improved, but the health care costs associated with such cancer treatment will be reduced as well, thus providing a significant benefit to society. Additionally, by more accurately choosing patients who do need chemotherapy the final outcome in terms of survival is expected to be better.

By conducting translational research in an integrated way, the project will ensure that the best facilities from the leading cancer research and treatment institutes will be shared, thus decreasing cost and increasing effectiveness.

“Improving the way we diagnose and treat breast cancer is crucial if we are to prevent many women receiving unnecessary, and costly, chemotherapy treatment in the future”, says Claire Horton, FP6UK’s National Contact Point for ’Life sciences, genomics and biotechnology for health. “The fight against cancer is a priority issue for the EU as it is estimated that our increasingly ageing population will lead to an extra 250,000 cancer diagnoses every year in Europe by 2020.

“The current Framework Programme (FP6) runs until 2006 and organisations wanting free information on how to access some of the 19 billion euros available should log on to http://fp6uk.ost.gov.uk or call central telephone support on 0870 600 6080.”

Dave Sanders | alfa
Further information:
http://fp6uk.ost.gov.uk

More articles from Health and Medicine:

nachricht The genes are not to blame
20.07.2018 | Technische Universität München

nachricht Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>